ReviewEndocrine2005
Genetics and proteomics of pituitary tumors.
Review in Endocrine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 43 citations in OpenAlex.
- Fshb-iCre mice are efficient and specific Cre deleters for the gonadotrope lineage.Molecular and cellular endocrinology · 2016Article
- Human Pituitary Adenoma Proteomics: New Progresses and Perspectives.Frontiers in endocrinology · 2016Review
- Pathogenesis analysis of pituitary adenoma based on gene expression profiling.Oncology letters · 2014Article
- Aggressive pituitary adenomas--diagnosis and emerging treatments.Nature reviews. Endocrinology · 2014Review
- Pituitary tumors in patients with MEN1 syndrome.Clinics (Sao Paulo, Brazil) · 2012Review
- Hand and foot abnormalities associated with genetic diseases.Hand (New York, N.Y.) · 2011Article
- Proteomic analysis of prolactinoma cells by immuno-laser capture microdissection combined with online two-dimensional nano-scale liquid chromatography/mass spectrometry.Proteome science · 2010Article
- E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors.Molecular endocrinology (Baltimore, Md.) · 2009Article
- Genetics, gene expression and bioinformatics of the pituitary gland.Hormone research · 2009Article
- Expression of MSX1 in human normal pituitaries and pituitary adenomas.Endocrine pathology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetics and proteomics determine structure and function of normal tissues, and the molecular alterations that underlie tumorigenesis result in changes in these aspects of tissue biology in neoplasms. We review the known genetic alterations in pituitary tumors. These include the oncogenic Gsalpha protein (GSP)-activating mutations, and pituitary tumor-derived fibroblast growth factor receptor-4 (ptd-FGFR4), as well as tumor suppressor gene mutations associated with multiple endocrine neoplasia type 1 (MEN1). Other candidates identified from expression profiling include pituitary tumor-transforming gene (PTTG), GADD45, and bone morphogenic protein (BMP)4. Proteomic changes in pituitary tumors include classical alterations identified by immunohistochemistry as well as epigenetic reductions in p27. The underlying mechanisms for dysregulated cell adhesive molecules including cadherins and FGFRs are reviewed. The combined use of genetic and proteomic approaches will enhance novel drug therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.